ChemOn

ChemOn is a leading South Korean contract research organization (CRO) specializing in non-clinical safety and efficacy evaluations for the pharmaceutical, biotechnology, and chemical industries. Founded in 2000, the company was the first private CRO in South Korea to receive Good Laboratory Practice (GLP) certification, establishing itself as a critical partner in the drug development lifecycle. ChemOn provides a comprehensive suite of services, including general toxicology, safety pharmacology, histopathology, and efficacy testing using specialized animal models. In 2022, the company was acquired by the HLB Group, a prominent healthcare conglomerate, and now operates as HLB ChemOn. The company continues to support global and domestic clients in navigating regulatory requirements for IND and NDA submissions.